Stockscreener 앱 받기
2.29
0.00%
0.00
시간 외 거래:
2.33
0.04
+1.75%
전일 마감가:
$2.29
열려 있는:
$2.3
하루 거래량:
81,283
Relative Volume:
0.03
시가총액:
$14.31M
수익:
$34.75M
순이익/손실:
$-24.76M
주가수익비율:
-0.1908
EPS:
-12
순현금흐름:
$-50.91M
1주 성능:
-4.58%
1개월 성능:
-36.03%
6개월 성능:
-87.66%
1년 성능:
-95.20%
1일 변동 폭
$2.20
$2.34
1주일 범위
$2.18
$2.415
52주 변동 폭
$2.15
$88.75
Allurion Technologies Inc Stock (ALUR) Company Profile
명칭
Allurion Technologies Inc
전화
508-647-4000
주소
11 HURON DR STE 200, NATICK
ALUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALUR
Allurion Technologies Inc
|
2.29 | 14.31M | 34.75M | -24.76M | -50.91M | -12.00 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Allurion Technologies Inc Stock (ALUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-02 | 개시 | TD Cowen | Buy |
| 2024-09-06 | 개시 | ROTH MKM | Buy |
| 2024-02-09 | 개시 | Jefferies | Buy |
Allurion Technologies Inc 주식(ALUR)의 최신 뉴스
4 Medical Product Stocks to Buy From a Challenging Industry - Zacks Investment Research
Allurion announces study on obesity treatment enhancement - MSN
Allurion Technologies gains approval for warrant repricing - Investing.com
12 Consumer Discretionary Stocks Moving In Monday's After-Market Session - Benzinga
(ALUR) Investment Report - news.stocktradersdaily.com
Allurion reschedules special stockholders meeting to April 10 By Investing.com - Investing.com India
Allurion reschedules special stockholders meeting to April 10 - Investing.com
Allurion Gives Shareholders More Time: Key Meeting Rescheduled to April 10 - Stock Titan
Allurion Announces Postponement of Special Meeting of Stockholders - Bluefield Daily Telegraph
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock By Investing.com - Investing.com Canada
Allurion Technologies CEO Gaur Shantanu acquires $26,800 in stock - Investing.com India
Allurion Technologies CEO Acquires 8,000 Shares - TradingView
Allurion Technologies’ Earnings Call: Growth Amid Challenges - TipRanks
Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail
Chardan holds Allurion stock at Neutral with a $2.50 target By Investing.com - Investing.com South Africa
Chardan holds Allurion stock at Neutral with a $2.50 target - Investing.com
Allurion Technologies Inc (ALUR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Allurion Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - BioSpace
TD Cowen Cuts Allurion Technologies' Price Target to $6 From $16, Buy Rating Maintained - MarketScreener
Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts By Investing.com - Investing.com South Africa
Earnings call transcript: Allurion Technologies’ Q4 2024 shows revenue drop, strategic shifts - Investing.com
Allurion Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLURION TECHNOLOGIES Earnings Results: $ALUR Reports Quarterly Earnings - Nasdaq
Earnings Scheduled For March 26, 2025 - Benzinga
What To Expect From Allurion Technologies Inc (ALUR) Q4 2024 Earnings - Yahoo Finance
Allurion surges on weight loss data from gastric balloon, GLP-1 combo treatment - MSN
Gold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings - Benzinga
Allurion Stock Soars on Promising GLP-1 Combo Results - Wall Street Pit
Promising Potential of Allurion Technologies’ Innovative Approach Supports Buy Rating - TipRanks
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Why Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Benzinga
US Stocks Likely To Open Lower, But 'Economic Conditions Don't Signal A Downturn,' Say Analysts As They Expect 'Resilient Earnings' To Lift EquitiesAllurion Technologies (NYSE:ALUR), Accenture (NYSE:ACN) - Benzinga
Allurion reports weight loss and muscle gain with new therapy By Investing.com - Investing.com South Africa
Allurion Technologies Reports Positive Ballon Combination Study Results; Shares Jump - MarketScreener
Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence - BioSpace
12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session - Benzinga
Allurion reports weight loss and muscle gain with new therapy - Investing.com India
Revolutionary Weight Loss Results: Allurion Balloon Plus Low-Dose GLP-1 Shows 20% Weight Loss, Preserves Muscle - StockTitan
ALLURION TECHNOLOGIES Earnings Preview: Recent $ALUR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Allurion’s Next-Generation Weight Loss Device Earns New Patents - Medical Product Outsourcing
Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Thursday - Defense World
Allurion to Report Fourth Quarter 2024 Financial Results on March 26, 2025 - The Joplin Globe
Q1 EPS Forecast for Allurion Technologies Cut by Analyst - Defense World
Allurion Technologies price target lowered to $16 on split-adjusted basis - TipRanks
Allurion Balloon Reintroduced in France - MPO-mag
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity - BioSpace
Allurion Technologies announces issuance of new patents on weight loss device - TipRanks
Allurion Announces Notification Of Issuance Of New U.S. Patents On Next-Generation Weight Loss Device For The Treatment Of Obesity - Marketscreener.com
Allurion Technologies Inc (ALUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
자본화:
|
볼륨(24시간):